{
  "meta": {
    "title": "Covid19_Mini_Test_-_New_Pattern_20_Questions",
    "url": "https://brainandscalpel.vercel.app/covid19-mini-test-new-pattern-20-questions-ff5ebbcb.html",
    "scrapedAt": "2025-11-30T12:45:28.928Z"
  },
  "questions": [
    {
      "text": "A 42-year-old asymptomatic woman is diagnosed with COVID 19 infection. Her CT chest is unremarkable. She was incidentally diagnosed with gall stones 2 months back and wishes to get an elective surgery done. As per the American Society of Anesthesiologists, how long is the suggested wait time for elective surgeries after diagnosis of COVID 19?",
      "choices": [
        {
          "id": 1,
          "text": "4 weeks from date of diagnosis"
        },
        {
          "id": 2,
          "text": "8 weeks  from date of diagnosis"
        },
        {
          "id": 3,
          "text": "8 weeks from date of recovery"
        },
        {
          "id": 4,
          "text": "4 weeks from date of recovery"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>For asymptomatic and mildly symptomatic COVID 19 positive patients, elective surgeries can be planned <strong>4 weeks from the date of diagnosis of COVID-19.</strong></p>\n<p>The American Society of Anesthesiologists (ASA) recommended waiting time for elective surgery from the date of diagnosis of COVID-19 infection are as follows:  </p>\n<ul>\n<li><strong>4 weeks</strong> for an asymptomatic patient or <strong>recovery from only</strong> <strong>mild</strong>, non-respiratory symptoms</li>\n<li><strong>6 weeks</strong> for symptomatic patients with cough/dyspnea <strong>not requiring hospitalization</strong></li>\n<li><strong>8 to 10 weeks</strong> for symptomatic patients who <strong>required hospitalization</strong> and/or <strong>diabetic</strong> patients and/or <strong>immunocompromised</strong></li>\n<li><strong>12 weeks</strong> for patients that had to be <strong>admitted to the ICU</strong> due to COVID 19  </li>\n</ul>\n<p>The American College of Surgeons recommends <strong>non-operative managemen</strong>t, if feasible and safe for the patient in surgical emergencies in a COVID-19 positive patient or is at high clinical suspicion of COVID-19.</p>\n<p>If the surgery is required in such patients, then proper<strong> personal protective equipment</strong> should be utilized and precautions to be taken to protect the health care team.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8479",
      "difficulty": "hard"
    },
    {
      "text": "A 16-year-old, healthy otherwise asymptomatic girl, who wanted to join back in her school after lockdown came to the local PHC for taking the rapid antigen test for COVID-19. She has tested positive. Which of the following is the next best appropriate step?",
      "choices": [
        {
          "id": 1,
          "text": "Repeat an RT-PCR test for her"
        },
        {
          "id": 2,
          "text": "Admit her to the COVID unit"
        },
        {
          "id": 3,
          "text": "Advise her for home isolation"
        },
        {
          "id": 4,
          "text": "Reconfirm with repeat RAT"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given scenario is an <strong>asymptomatic mild case of COVID-19</strong> with <strong>no risk factors</strong> who can be recommended home isolation for a duration of 10 days starting from symptom onset. Repeating the RAT test is not recommended. A single Positive RAT is sufficient enough to make the diagnosis of COVID19.</p><p>Isolation is the separation and restriction of movements or activities of persons who are sick, to prevent the transmission of disease. Eligibility for home isolation:</p>\n<ul>\n<li aria-level=\"1\">The person should be clinically assigned as a mild case or asymptomatic case by the treating medical officer.</li>\n<li aria-level=\"1\">Such cases should have the requisite facility at their residence for self-isolation and also for quarantining the family contacts.</li>\n<li aria-level=\"1\">The caregiver should be available and a communication link between the caregiver and the hospital should be established.</li>\n<li aria-level=\"1\">The patient must monitor his health regularly and inform his health status to the district surveillance officer.</li>\n</ul>\n<p>The patient can end home isolation after 10 days of onset of symptoms (or date of sampling for pre-symptomatic cases) and no fever for 3 days. There is no need for testing after the home isolation period is over.</p>\n<p>The patient should seek medical help if he develops:</p>\n<ul>\n<li aria-level=\"1\">Difficulty in breathing</li>\n<li aria-level=\"1\">Persistent pain/pressure in the chest</li>\n<li aria-level=\"1\">Mental confusion or inability to arouse</li>\n<li>Dip in oxygen saturation (SpO2 &lt; 94% on room air)</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a4fd35c45c3b46879b25388976adb992x600x804.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8473",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements are true about COVID 19?<div class='question-desc-html'><ol>\n<li>It is caused by an enveloped RNA virus with&nbsp;club-shaped spikes</li>\n<li>Biosafety level 2 is the minimum required for the culture of this virus</li>\n<li>FELUDA based on CRISPR gene-editing technology is a strip test that could detect the SARS COV-2&nbsp;genes</li>\n<li>KAVACH ELISA is used for antigen detection</li>\n<li>SARS COV 2 belongs to the family called Orthomyxoviridae</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 4, and 5"
        },
        {
          "id": 2,
          "text": "2, 3,  and 4"
        },
        {
          "id": 3,
          "text": "1, 2, 3"
        },
        {
          "id": 4,
          "text": "1 and 3 only"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Statements 1 and 3 are true about COVID-19. <strong>SARS - COV2</strong> is an<strong>&nbsp;enveloped RNA virus</strong>&nbsp;with <strong>club-shaped spikes</strong> and <strong>FELUDA</strong> based on the <strong>CRISPR gene-editing</strong> technology is a strip test that can <strong>detect SARS COV 2 genes.</strong></p>\n<p>A biosafety level cabinet <strong>BSL of level 3</strong> is required for <strong>culturing</strong> the virus while a <strong>level 2</strong> would suffice for <strong>specimen handling or molecular testing</strong> of the virus. <strong>KAVACH ELISA</strong> is for <strong>antibody detection</strong> of COVID-19. Coronavirus belongs to the family of <strong>Coronaviridae.</strong></p>\n<p>Coronaviruses are enveloped positive-sense, single-stranded RNA viruses with an unsegmented genome, and they exhibit&nbsp;<strong>helical</strong>&nbsp;<strong>symmetry</strong>.&nbsp;</p>\n<p>The coronaviridiae have a single unsegmented&nbsp;<strong>ss (+) RNA</strong>&nbsp;which is, in fact, the largest genome among RNA viruses. They are about 120 - 160 nm in size and contain a&nbsp;<strong>helical nucleocapsid.&nbsp;</strong>It also has&nbsp;<strong>spike proteins - S1 and S2.</strong>&nbsp;They are responsible for the&nbsp;<strong>host specificty</strong>, faster spread of the disease and it is highly&nbsp;<strong>suscpetible to mutations</strong>. While&nbsp;<strong>S1 protein</strong>&nbsp;is involved in the&nbsp;<strong>attachment of the virus</strong>&nbsp;with&nbsp;<strong>ACE-2 receptor</strong>, S2 protein is involved in virus-host cell fusion.&nbsp;</p>\n<p>The virus responsible for the recent pandemic that started in 2019 is named&nbsp;<strong>SARS-CoV-2</strong>&nbsp;(severe acute respiratory syndrome- coronavirus-2) and the disease it causes has been named&nbsp;<strong>coronavirus disease 2019</strong>&nbsp;(abbreviated COVID-19).&nbsp;</p>\n<p>SARS-CoV-2 is a member of the order Nidovirales, family Coronaviridae, subfamily Orthocoronavirinae,<strong>&nbsp;genera Betacoronavirus, and sub-genus Sarbecovirus.&nbsp;</strong></p><hr><h3>Related Pearl: Types of symmetry of viruses</h3><table>\n<tbody>\n<tr>\n<td><strong>Type of symmetry&nbsp;</strong></td>\n<td><strong>Examples</strong></td>\n</tr>\n<tr>\n<td><strong>Naked icosahedral</strong></td>\n<td>\n<p>Poliovirus</p>\n<p>Adenovirus</p>\n<p>Hepatitis A virus</p>\n</td>\n</tr>\n<tr>\n<td><strong>Naked helical</strong></td>\n<td>Tobacco mosaic virus</td>\n</tr>\n<tr>\n<td><strong>Enveloped icosahedral</strong></td>\n<td>\n<p>Herpes virus</p>\n<p>Yellow fever virus</p>\n<p>Rubella virus</p>\n</td>\n</tr>\n<tr>\n<td><strong>Enveloped helical</strong></td>\n<td>\n<p>Corona virus</p>\n<p>Rabies virus</p>\n<p>Influenza virus</p>\n<p>Parainfluenza virus</p>\n<p>Mumps virus</p>\n<p>Measles virus</p>\n</td>\n</tr>\n<tr>\n<td><strong>Complex</strong></td>\n<td>\n<p>Poxvirus</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Laboratory Biosafety Levels (BSL)</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Biosafety level</strong></td>\n<td><strong>Lab practices</strong></td>\n<td><strong>Safety Equipment</strong></td>\n<td><strong>Facility</strong></td>\n</tr>\n<tr>\n<td><strong>BSL 1</strong></td>\n<td>\n<p>Work on open lab benches or tables.</p>\n<p>Good microbiological techniques followed</p>\n</td>\n<td>PPE (lab coats, gloves, eye protection) are worn as needed.</td>\n<td>\n<p>Sink for hand washing.</p>\n<p>Separate doors from the rest of the facility.</p>\n</td>\n</tr>\n<tr>\n<td><strong>BSL 2</strong></td>\n<td>Access restricted to the laboratory</td>\n<td>\n<p>Appropriate PPE (lab coats, gloves, eye protection, and face shields).</p>\n<p>Biological safety cabinets (BSC) to prevent potential aerosols.</p>\n<p>Autoclave or alternative method for decontamination</p>\n</td>\n<td>\n<p>Sink and eyewash easily available.</p>\n<p>Self-closing doors.&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td><strong>BSL 3</strong></td>\n<td>\n<p>Access restricted and controlled at all times.</p>\n<p>Medical surveillance of laboratory workers.</p>\n</td>\n<td>\n<p>Appropriate PPE must be worn, and respirators might be required.</p>\n<p>BSC for all activities.</p>\n</td>\n<td>\n<p>Hands-free sink and eyewash.</p>\n<p>Directional airflow from clean areas towards potentially contaminated areas.</p>\n<p>Entrance to the lab is through 2 self-closing and interlocked doors.</p>\n</td>\n</tr>\n<tr>\n<td><strong>BSL 4</strong></td>\n<td>\n<p>Change clothing before entering and shower upon exiting.</p>\n<p>Decontaminate all materials before exiting.</p>\n</td>\n<td>\n<p>BSC and full-body, air-supplied, positive pressure suit.</p>\n<p>Double-ended autoclave (through the wall).</p>\n</td>\n<td>\n<p>Laboratory in a separate building or isolated in a restricted zone.</p>\n<p>Dedicated supply and exhaust air, as well as vacuum lines and decontamination systems.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8463",
      "difficulty": "medium"
    },
    {
      "text": "In which of the following patients, would you administer Covidshield vaccination?<div class='question-desc-html'><ol>\n<li><span data-preserver-spaces=\"true\">A 51-year-old man who underwent hematopoietic stem cell transplantation 5 weeks ago for aplastic anemia.&nbsp;</span></li>\n<li><span data-preserver-spaces=\"true\">A 60-year-old man with a history of type-2 diabetes mellitus.&nbsp;</span></li>\n<li><span data-preserver-spaces=\"true\">A 32-year-old woman who received TT immunization 20 days back following a trivial fall from a bike.</span></li>\n<li><span data-preserver-spaces=\"true\">A 45-year-old man on dialysis three times a week for chronic kidney disease.</span></li>\n<li><span data-preserver-spaces=\"true\">A 40-year-old woman on insulin therapy for type-1 diabetes mellitus.&nbsp;</span></li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3"
        },
        {
          "id": 2,
          "text": "1, 2, 4, 5"
        },
        {
          "id": 3,
          "text": "2, 3, 4, 5"
        },
        {
          "id": 4,
          "text": "3, 4, 5"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The&nbsp;<span data-preserver-spaces=\"true\">51-year-old man</span> should receive&nbsp;COVID-19 vaccination<strong>&nbsp;</strong>at least<strong> 3 months after hematopoietic cell transplantation</strong> (and not 5 weeks)&nbsp;to&nbsp;maximize vaccine efficacy.&nbsp;</p>\n<p><strong>Graft-versus-host disease</strong> and immunosuppressive regimens like systemic corticosteroids can blunt the immune responses to vaccination. Delay of vaccination until<strong> immunosuppressive therapy</strong> is reduced can be considered.&nbsp;</p>\n<p>Consider additional risk factors linked to <strong>adverse COVID-19 complications</strong> including, but not limited to:&nbsp;</p>\n<ul>\n<li>Patients with advanced age (eg, &ge;65 years of age)&nbsp;</li>\n<li>Patients with comorbidities (eg, chronic pulmonary, cardiovascular, or renal disease)&nbsp;</li>\n<li>Social and demographic factors</li>\n</ul>\n<p>COVID-19 vaccines should be prioritized over other vaccines. A gap of&nbsp;<strong>14 days</strong>&nbsp;is recommended between COVID-19 vaccines and any other vaccine.&nbsp;</p>\n<p>If COVID vaccine has been given first, then TT vaccine can be given on the same day. If TT vaccine have been given first, then wait for 14 days to give COVID vaccine.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8475",
      "difficulty": "medium"
    },
    {
      "text": "The following equipment with a sample was sent from the COVID-19 positive ward for testing. Where should the empty container be disposed of?",
      "choices": [
        {
          "id": 1,
          "text": "Yellow bin"
        },
        {
          "id": 2,
          "text": "Red bin"
        },
        {
          "id": 3,
          "text": "Blue bin"
        },
        {
          "id": 4,
          "text": "Black bin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span data-preserver-spaces=\"true\">The image shows an</span><strong><span data-preserver-spaces=\"true\">&nbsp;Eppendorf micro-centrifugation tube</span></strong><span data-preserver-spaces=\"true\">. It should be discarded in <strong>r</strong></span><strong><span data-preserver-spaces=\"true\"><strong>ed</strong> bin.</span></strong></p>\n<p>These<strong><span data-preserver-spaces=\"true\">&nbsp;</span></strong><span data-preserver-spaces=\"true\">are single-use disposable tubes used for storing human test samples (except blood) for <strong>in-vitro testing</strong>. The tube is sensitive to temperature and seals may breach in higher temperatures.</span></p><hr><h3>Related Pearl: Biomedical Waste (BMW) Management -COVID 19</h3><p>In addition to the current BMW Management rules, the following measures are proposed</p>\n<ul>\n<li>To report opening/operation of COVID 19 Ward/ICU/Lab/Collection Centre to <strong>SPCB</strong> (State Pollution Control Board) and <strong>CBWTF</strong> (Common Biomedical Waste Treatment Facility) in that area</li>\n<li>Dedicated sanitation workers deputed only to collect COVID 19 BMW</li>\n<li>It is mandatory for all BMW bags and containers from COVID 19 areas to carry <strong>\"COVID 19 WASTE\"</strong> label</li>\n<li>Keep separate colour coded bins with <strong>foot operated lids</strong></li>\n<li>The inner and outer surfaces of these containers must be disinfected daily with <strong>1% sodium hypochlorite</strong> solution</li>\n<li>To ensure no leaks, <strong>double layers&nbsp;</strong>(2 bags) are used</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td><strong>COLOUR OF THE BIN</strong></td>\n<td><strong>PERSONAL PROTECTIVE EQUIPMENT(PPE)</strong></td>\n<td><strong>OTHER WASTE</strong></td>\n</tr>\n<tr>\n<td><strong>Red Bin</strong></td>\n<td>\n<ul>\n<li>Goggles</li>\n<li>Face shield&nbsp;</li>\n<li>Splash-proof apron</li>\n<li>Plastic coverall</li>\n<li>Hazmat suit</li>\n<li>Nitrile gloves</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Used gloves</li>\n</ul>\n<p><strong>Laboratory waste</strong></p>\n<ul>\n<li>Pre-treated viral transport media</li>\n<li>Plastic vials and cryovials</li>\n<li>Vacutainers</li>\n<li>Eppendorf tubes</li>\n<li>Pipette tips</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Yellow Bin</strong></td>\n<td>\n<ul>\n<li>Used mask(triple layer mask, N95 mask)</li>\n<li>Head cover/Cap, Shoe cover</li>\n<li>Disposable linen gown&nbsp;</li>\n<li>Non-plastic/Semi-plastic coverall</li>\n</ul>\n</td>\n<td>\n<p>&nbsp;</p>\n<ul>\n<li>Diapers with feces of immobile COVID 19 patients&nbsp;</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b8f6784a86304d46b7e0f67982eaea1f.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8477",
      "difficulty": "medium"
    },
    {
      "text": "A young girl, who recently recovered from COVID-19, presents with fever, abdominal pain and rashes for 4 days. On examination, strawberry tongue is observed and cervical nodes are found to be enlarged bilaterally. What is the likely diagnosis?<div class='question-desc-html'><p>HR: 110/min</p>\n<p>BP: 80/60 mm Hg</p>\n<p>RR: 20/min</p>\n<p>CRP: 10 mg/L</p>\n<p>ESR: 76mm/hr.</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Kawasaki disease"
        },
        {
          "id": 2,
          "text": "Multisystem inflammatory syndrome in children"
        },
        {
          "id": 3,
          "text": "Bacterial sepsis"
        },
        {
          "id": 4,
          "text": "Toxic shock syndrome"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This is a case of <strong>m</strong><strong>ultisystem inflammatory syndrome in children (MIS-C)</strong>, associated with<strong> COVID-19</strong> infection.</p>\n<p><strong>Diagnostic criteria for MIS-C:</strong></p>\n<p>Children and adolescents 0&ndash;18 years of age with fever &ge;3 days</p>\n<p>AND two of these:</p>\n<ul>\n<li aria-level=\"1\">Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (palmoplantar erythema,&nbsp;lip hyperemia, periorbital erythema and edema, strawberry tongue, and malar erythema)</li>\n<li aria-level=\"1\">Hypotension or shock.</li>\n<li aria-level=\"1\">Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities&nbsp;(including ECHO findings or elevated Troponin/NT-proBNP)</li>\n<li aria-level=\"1\">Evidence of coagulopathy&nbsp;(PT, PTT, elevated D-Dimers)</li>\n<li aria-level=\"1\">Acute gastrointestinal problems (diarrhoea, vomiting, or abdominal pain)</li>\n</ul>\n<p>AND</p>\n<p>Elevated ESR(&gt;40 mm), C-reactive protein (&gt;5 mg/L), or procalcitonin.</p>\n<p>AND</p>\n<p>No other obvious microbial cause of inflammation including bacterial sepsis, staphylococcal or streptococcal shock syndromes.</p>\n<p>AND</p>\n<p>Evidence of COVID-19 (RT-PCR, antigen test,&nbsp;or serology positive), or likely contact with patients with COVID-19.</p>\n<p><strong>Types of MIS-C</strong>:</p>\n<ul>\n<li>MIS-C with shock/multi-organ dysfunction</li>\n<li>Kawasaki phenotype</li>\n<li>MIS-C without shock</li>\n</ul>\n<p>MIS-C is treated with <strong>IV methylprednisolone</strong>. The dose can be increased in patients with shock. If the condition does not improve for 48-72 hours, specialists can be consulted for the addition of biologicals to the treatment regimen.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7149",
      "difficulty": "easy"
    },
    {
      "text": "A G2P1 woman presents to the clinic at 37 weeks of gestation with mild dyspnea. Her husband was COVID positive and now she has tested positive for COVID 19. She is febrile and you note that she is tachypneic on examination. Which of the following is/are incorrect regarding the management of this patient?<div class='question-desc-html'><ol>\n<li>She needs admission to a tertiary care center.</li>\n<li>Maternal heart rate, respiratory rate BP, and temperature should be measured at least 3-4 times a day</li>\n<li>Fetal heart rate should be measured once in 2 days</li>\n<li>Betamethasone injection should not be given as it can worsen COVID in the mother</li>\n<li>Once delivered, RT-PCR of the New-born should be done</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 4, 5"
        },
        {
          "id": 2,
          "text": "1, 2, 4"
        },
        {
          "id": 3,
          "text": "1, 2, 5"
        },
        {
          "id": 4,
          "text": "3, 4"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>As the pregnant female has tested positive for SARS COV 2 she requires admission to a tertiary care center. Once admitted, maternal surveillance should include maternal heart rate, respiratory rate BP, and temperature measurement at least 3-4 times a day along with requisite chest imaging using X-ray or CT.</p>\n<p>As part of fetal monitoring, <strong>FHR should be measured on a daily basis</strong>, not once in two days. Since the patient is at 37 weeks, betamethasone should be given to facilitate fetal maturation. <strong>Betamethasone can be given</strong> to mothers between 34-37 weeks. IV antibiotics can be added as per the local protocols.</p>\n<p>Once delivered, RT-PCR of the New-born should be done.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8320",
      "difficulty": "medium"
    },
    {
      "text": "Working as a duty doctor in a COVID care centre, you were trained on sanitation techniques, donning, doffing of PPE and other preventive measures to reduce the incidence of disease. You were recommended to use alcohol-based hand rubs to curtail the spread of COVID-19 infection. The microbiological basis for the same would be?",
      "choices": [
        {
          "id": 1,
          "text": "COVID-19 virus has spike proteins"
        },
        {
          "id": 2,
          "text": "COVID-19 virus has an ss-RNA"
        },
        {
          "id": 3,
          "text": "COVID-19 virus has a lipid envelope"
        },
        {
          "id": 4,
          "text": "COVID-19 virus has a glycoprotein capsid"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Alcohol-based hand rubs</strong> are preferred because <strong>COVID 19 virus has a lipid envelope</strong>&nbsp;that contributes to its susceptibility to lipid solvents.&nbsp;</p>\n<p>Coronaviruses are <strong>enveloped helically symmetrical</strong>&nbsp;viruses. Alcohol, especially ethanol present in the hand rubs, dissolves the lipid envelope and denatures the proteins present. This leads to membrane disruption and inhibition of the metabolism, as depicted below:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/cf6db79d20a44b199b76dd895ca8107bx800x292.JPEG\" alt=\"Explanation Image\"><p>The Coronaviridiae have a single unsegmented <strong>ss (+) RNA</strong> which is, in fact, the largest genome among RNA viruses. They are about 120 - 160 nm in size and contain a <strong>helical nucleocapsid.&nbsp;</strong>They have club-shaped or petal-shaped projections that are widely spaced on the outer surface of the envelope, suggestive of a <strong>solar corona.</strong></p>\n<p>The virus has <strong>spike proteins - S1 and S2 </strong>which&nbsp;are responsible for the <strong>host specificity</strong>, faster spread of the disease, and make it highly <strong>susceptible to mutations</strong>. While <strong>S1 protein</strong> is involved in the <strong>attachment of the virus</strong> with the&nbsp;<strong>ACE-2 receptor</strong>, S2 protein is involved in virus-host cell fusion.&nbsp;</p>\n<p>The virus responsible for the pandemic that started in 2019 is named <strong>SARS-CoV-2</strong> (severe acute respiratory syndrome- coronavirus-2) and the disease it causes has been named <strong>coronavirus disease 2019</strong> (abbreviated COVID-19).&nbsp;</p>\n<p>SARS-CoV-2 is a member of the order Nidovirales, family Coronaviridae, subfamily Orthocoronavirinae,&nbsp;and is considered to be a new member of the <strong>genus Betacoronavirus.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/105418143db243799a8c028a61bf7753x1280x1089.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Methods of sterilisation</h3><table>\n<tbody>\n<tr>\n<td><strong>Method of disinfection or sterilisation</strong></td>\n<td><strong>Material</strong></td>\n</tr>\n<tr>\n<td>Red Heat</td>\n<td>Inoculating wire loop, tip of forceps</td>\n</tr>\n<tr>\n<td>Incineration</td>\n<td>Contaminated clothes, animal carcasses, plastics like polythene</td>\n</tr>\n<tr>\n<td>Hot air oven</td>\n<td>Glasswares, scalpels, forceps, cutting instruments, test tubes</td>\n</tr>\n<tr>\n<td>Inspissator</td>\n<td>Heat labile culture media containing egg, sugar or serum</td>\n</tr>\n<tr>\n<td>Autoclave</td>\n<td>Culture media, dressings, gloves, aprons, all instruments except sharps, suture materials except catgut</td>\n</tr>\n<tr>\n<td>Isopropyl alcohol</td>\n<td>Clinical thermometers, stethoscopes, probes</td>\n</tr>\n<tr>\n<td>Methyl alcohol</td>\n<td>Fungal spores</td>\n</tr>\n<tr>\n<td>\n<p>Beta propiolactone/</p>\n<p>formaldehyde</p>\n</td>\n<td>Fumigation of operating theatres, wards and labs</td>\n</tr>\n<tr>\n<td>2% gluteraldehyde</td>\n<td>Cystoscopes, bronchoscopes, fibre-optic endoscopes, plastic ETT, face masks</td>\n</tr>\n<tr>\n<td>Plasma sterilisation</td>\n<td>Arthroscopes, urethroscopes</td>\n</tr>\n<tr>\n<td>Ethylene oxide</td>\n<td>Heart lung machines, respirators, dental equipments, sutures, books, clothings</td>\n</tr>\n<tr>\n<td>Filtration (Seitz filters)</td>\n<td>Bacterial vaccines, intravenous solutions</td>\n</tr>\n<tr>\n<td>5% cresol, hot air oven</td>\n<td>Sharp instruments</td>\n</tr>\n<tr>\n<td>\n<p>Ionising radiation</p>\n<p>(Cold air sterilization)</p>\n</td>\n<td>Catgut, swabs, plastic, syringes, needles, gloves, catheters, grafts</td>\n</tr>\n<tr>\n<td>Chlorhexidine</td>\n<td>Disinfecting surgeon&rsquo;s hands prior to surgery</td>\n</tr>\n<tr>\n<td>Iodophor</td>\n<td>Disinfecting surgical site prior to surgery</td>\n</tr>\n<tr>\n<td>70% ethanol</td>\n<td>Disinfectant skin prior to venepuncture or immunisation</td>\n</tr>\n<tr>\n<td>Thiomersal</td>\n<td>Preservative in vaccine</td>\n</tr>\n<tr>\n<td>Silver sulfadiazine</td>\n<td>Cleanse burn wounds</td>\n</tr>\n<tr>\n<td>Hypochlorite</td>\n<td>Cleanup of blood spill from a patient with hepatitis B or C</td>\n</tr>\n<tr>\n<td>Hydrogen peroxide</td>\n<td>Cleanse wounds</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8319",
      "difficulty": "medium"
    },
    {
      "text": "You are working in a covid ward. After doffing, where will you dispose of the plastic coverall?",
      "choices": [
        {
          "id": 1,
          "text": "Red bin"
        },
        {
          "id": 2,
          "text": "Black bag"
        },
        {
          "id": 3,
          "text": "Yellow bin"
        },
        {
          "id": 4,
          "text": "Blue bin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>plastic coverall</strong> used by a healthcare worker during the&nbsp;<strong>COVID-19</strong> pandemic should be disposed of in the <strong>red bin</strong>.</p><hr><h3>Related Pearl: Biomedical Waste (BMW) Management -COVID 19</h3><p>In addition to the current BMW Management rules, the following measures are proposed</p>\n<ul>\n<li>To report opening/operation of COVID 19 Ward/ICU/Lab/Collection Centre to <strong>SPCB</strong> (State Pollution Control Board) and <strong>CBWTF</strong> (Common Biomedical Waste Treatment Facility) in that area</li>\n<li>Dedicated sanitation workers deputed only to collect COVID 19 BMW</li>\n<li>It is mandatory for all BMW bags and containers from COVID 19 areas to carry <strong>\"COVID 19 WASTE\"</strong> label</li>\n<li>Keep separate colour coded bins with <strong>foot operated lids</strong></li>\n<li>The inner and outer surfaces of these containers must be disinfected daily with <strong>1% sodium hypochlorite</strong> solution</li>\n<li>To ensure no leaks, <strong>double layers&nbsp;</strong>(2 bags) are used</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td><strong>COLOUR OF THE BIN</strong></td>\n<td><strong>PERSONAL PROTECTIVE EQUIPMENT(PPE)</strong></td>\n<td><strong>OTHER WASTE</strong></td>\n</tr>\n<tr>\n<td><strong>Red Bin</strong></td>\n<td>\n<ul>\n<li>Goggles</li>\n<li>Face shield&nbsp;</li>\n<li>Splash-proof apron</li>\n<li>Plastic coverall</li>\n<li>Hazmat suit</li>\n<li>Nitrile gloves</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Used gloves</li>\n</ul>\n<p><strong>Laboratory waste</strong></p>\n<ul>\n<li>Pre-treated viral transport media</li>\n<li>Plastic vials and cryovials</li>\n<li>Vacutainers</li>\n<li>Eppendorf tubes</li>\n<li>Pipette tips</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Yellow Bin</strong></td>\n<td>\n<ul>\n<li>Used mask(triple layer mask, N95 mask)</li>\n<li>Head cover/Cap, Shoe cover</li>\n<li>Disposable linen gown&nbsp;</li>\n<li>Non-plastic/Semi-plastic coverall</li>\n</ul>\n</td>\n<td>\n<p>&nbsp;</p>\n<ul>\n<li>Diapers with feces of immobile COVID 19 patients&nbsp;</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3379",
      "difficulty": "medium"
    },
    {
      "text": "A 32-year-old female diagnosed with mild-moderate COVID19 gave birth to a healthy, term neonate. It was a spontaneous vaginal delivery at 38 weeks of gestation with uneventful intrapartum history. The APGAR score of the baby at 1 and 5 minutes were 8/10 and 9/10 respectively. You are the rotating intern from the department of pediatrics. Which of the following would you be correct to advise?<div class='question-desc-html'><ol>\n<li>Colocation should be avoided if possible.</li>\n<li>If the mother is not willing to stay separated, you can arrange for a screen between the two.&nbsp;</li>\n<li>A dedicated breast pump must not be provided to the mother. The breast pump in the ward can be used as usual.</li>\n<li>In case she does not have a caregiver, you can ask the mother to feed the baby herself wearing a face mask and after performing hand hygiene.</li>\n<li>The newborn should be kept &ge;6 feet away from the ill mother.</li>\n</ol>\n<p>&nbsp;</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3, 4, 5"
        },
        {
          "id": 2,
          "text": "1, 2, 4, 5"
        },
        {
          "id": 3,
          "text": "3 and 5 only"
        },
        {
          "id": 4,
          "text": "1, 3 and 4 only"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The correct advice would include 1, 2, 4, and 5.</p>\n<p>Guidelines for Neonatal management of a baby born to COVID19 positive mother include:</p>\n<ol>\n<li aria-level=\"1\">Mother and child should be separated from each other.</li>\n<li aria-level=\"1\">Colocation / Rooming-in should be avoided as and when possible.</li>\n<li aria-level=\"1\">If the situation demands rooming-in or if the mother does not have a healthy caregiver or if she is not consenting to the separation, arrangements have to be made accordingly. A screen can be placed in between the two and a distance of 6 feet minimum can be maintained between the two.&nbsp;</li>\n<li aria-level=\"1\">Breastfeeding is not contraindicated in COVID19 infected mothers.&nbsp;</li>\n<li aria-level=\"1\">Mother can express the breastmilk using a dedicated breast pump and ask the caregiver to feed the child. If a dedicated breast pump is not available,&nbsp;all parts<br />that come into contact with breast milk should be thoroughly washed and the entire pump should be appropriately disinfected as per the manufacturer&rsquo;s instructions after each pumping session.</li>\n<li aria-level=\"1\">In case the caregiver is not available, she can feed the child directly wearing a face mask and she must follow hand hygiene properly.</li>\n</ol>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8471",
      "difficulty": "medium"
    },
    {
      "text": "A 48-year-old CKD patient had tested positive for COVID-19 infection. He was also put on a ventilator due to worsening saturation but, unfortunately, he passed away. A pathologist working in your hospital is researching histopathology of COVID19 infection and takes a section of the diseased lung. She notices the image shown below under her microscope. Which of the following is wrong about the given finding?",
      "choices": [
        {
          "id": 1,
          "text": "The image shows diffuse alveolar damage"
        },
        {
          "id": 2,
          "text": "It is specific to COVID 19 pneumonia"
        },
        {
          "id": 3,
          "text": "This is the commonest pattern of lung lesions in patients with COVID-19"
        },
        {
          "id": 4,
          "text": "Commonly associated with mononuclear cell infiltration"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span data-preserver-spaces=\"true\">The given HP slide shows <strong>Diffuse alveolar damage</strong> and it is <strong>non-specific</strong> to COVID 19 pneumonia.</span></p>\n<p><span data-preserver-spaces=\"true\">Though diffuse alveolar damage is the <strong>most common finding</strong> in the histopathological analysis of COVID-19 infected lungs, it is not specific to COVID-19. It can also be seen in <strong>ARDS, burns, near-drowning</strong>. </span></p>\n<p><span data-preserver-spaces=\"true\">Other findings seen in the lungs infected with COVID-19 include:</span></p>\n<ul>\n<li><strong>Hyaline membrane formation</strong></li>\n<li><span data-preserver-spaces=\"true\">Desquamation of pneumocytes</span></li>\n<li><span data-preserver-spaces=\"true\">Fibrin deposits in the lungs</span></li>\n<li><strong>Inflammation with mononuclear cells </strong></li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/8eb4275e03f641cc8e2f1da7e598b720.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8466",
      "difficulty": "medium"
    },
    {
      "text": "You are posted as an intern in casualty. An elderly 60-year-old man is brought to you with complaints of chest pain. He has tested positive for COVID. Which of the following features will prompt you to get this patient admitted to dedicated COVID Health Centre?<div class='question-desc-html'><p>A. Respiratory rate of 25/min<br />B. SpO2 93%<br />C. Multiple comorbidities<br />D. Chest pain<br />E. Age</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "A & B only"
        },
        {
          "id": 2,
          "text": "A, B, C, & E only"
        },
        {
          "id": 3,
          "text": "A, B & C only"
        },
        {
          "id": 4,
          "text": "A, B, C, D & E"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>A, B, C &amp; E</strong> are clinical criteria of admission under COVID-19 ward.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/43d094ce4619426698ff0444460bf1f9x1280x4371.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6953",
      "difficulty": "medium"
    },
    {
      "text": "Which case scenarios along with the drugs prescribed are inappropriate?<div class='question-desc-html'><ol>\n<li><span data-preserver-spaces=\"true\">A man on anti-retroviral therapy with severe COVID pneumonia- Tocilizumab</span></li>\n<li><span data-preserver-spaces=\"true\">A non-hospitalized middle-aged diabetic man with mild COVID pneumonia- Bamlanivimab</span></li>\n<li><span data-preserver-spaces=\"true\">A mother on post-partum day 3 with moderate COVID pneumonia maintaining with NIPPV- Remedisivir</span></li>\n<li><span data-preserver-spaces=\"true\">A woman with COVID-19 disease- Convalescent plasma therapy</span></li>\n<li><span data-preserver-spaces=\"true\">A woman with moderate COVID pneumonia on supplemental oxygen- Dexamethasone</span></li>\n</ol>\n<p><span data-preserver-spaces=\"true\">&nbsp;</span></p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3, 4, 5"
        },
        {
          "id": 2,
          "text": "1, 2, 3, and 4 only"
        },
        {
          "id": 3,
          "text": "3, 4 and 5"
        },
        {
          "id": 4,
          "text": "1 and 2 only"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span data-preserver-spaces=\"true\">The correct answer is <strong>1, 2, 3, and 4.</strong></span></p>\n<ol>\n<li><span data-preserver-spaces=\"true\">Tocilizumab is <strong>contraindicated</strong> in<strong> HIV-positive</strong> patients and those with active bacterial or fungal infection.</span></li>\n<li><span data-preserver-spaces=\"true\">Bamlanivimab is <strong>not</strong>&nbsp;</span><span data-preserver-spaces=\"true\">authorized for patients with&nbsp;<strong>mild&nbsp;</strong></span><span data-preserver-spaces=\"true\">COVID-19 pneumonia who are not at&nbsp;a high risk for <strong>hospitalization</strong>.</span></li>\n<li><span data-preserver-spaces=\"true\">Remedisivir is <strong>contraindicated </strong>in<strong> postnatal</strong> lactating women.</span></li>\n<li><span data-preserver-spaces=\"true\">Convalescent plasma therapy is&nbsp;<strong>no longer recommended</strong>&nbsp;in the management of COVID patients.</span></li>\n</ol>\n<p><strong><span data-preserver-spaces=\"true\">Tocilizumab</span></strong><span data-preserver-spaces=\"true\">&nbsp;acts by <strong>IL-6 inhibition</strong>. It may be considered in moderate-severe COVID patients with progressively increasing oxygen requirements and mechanically ventilated patients not improving despite the use of steroids. Patients should be carefully monitored for secondary infections and neutropenia after treatment with tocilizumab. It is contraindicated in:</span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">HIV&nbsp;</span></li>\n<li><span data-preserver-spaces=\"true\">Active infections (systemic bacterial/fungal)</span></li>\n<li><span data-preserver-spaces=\"true\">Tuberculosis</span></li>\n<li><span data-preserver-spaces=\"true\">Active hepatitis</span></li>\n<li><span data-preserver-spaces=\"true\">Absolute neutrophil count &lt; 2000/mm3</span></li>\n<li><span data-preserver-spaces=\"true\">Platelet count &lt; 1,00,000/mm3</span></li>\n</ul>\n<p><strong><span data-preserver-spaces=\"true\">Bamlanivimab</span></strong><span data-preserver-spaces=\"true\">&nbsp;is a monoclonal antibody directed against the&nbsp;</span><strong><span data-preserver-spaces=\"true\">spike protein</span></strong><span data-preserver-spaces=\"true\">&nbsp;of SARS-CoV-2. The FDA has issued an <strong>emergency use authorization</strong> for bamlanivimab for the treatment of adult and pediatric mild to moderate COVID patients (12 years of age and older weighing at least 40 kilograms) who are at high risk for progressing to severe COVID-19 and/or hospitalization.&nbsp;</span><span data-preserver-spaces=\"true\">Possible side effects include anaphylaxis and infusion-related reactions, nausea, diarrhea, dizziness, headache, itching, and vomiting. There is&nbsp;</span><strong><span data-preserver-spaces=\"true\">no specific contraindication</span></strong><span data-preserver-spaces=\"true\">&nbsp;for this drug.&nbsp;</span></p>\n<p><strong><span data-preserver-spaces=\"true\">Remdesivir&nbsp;</span></strong><span data-preserver-spaces=\"true\">is an</span><span data-preserver-spaces=\"true\">&nbsp;antiviral drug that works by <strong>inhibiting RNA-dependent RNA polymerase</strong>. It may be considered in moderate and severe hospitalized COVID patients requiring supplemental oxygen/oxygen delivery through a high flow device/ noninvasive ventilation/ invasive mechanical ventilation/ ECMO.&nbsp;</span><span data-preserver-spaces=\"true\">It is contraindicated in:&nbsp;</span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\">AST/ALT &gt; 5 times upper limit of normal</span></li>\n<li><span data-preserver-spaces=\"true\">Severe renal impairment (i.e., eGFR &lt; 30ml/min/m2 or need for hemodialysis)&nbsp;</span></li>\n<li><span data-preserver-spaces=\"true\">Pregnancy or lactating females&nbsp;</span></li>\n<li><span data-preserver-spaces=\"true\">Children &lt;12 years of age</span></li>\n</ul>\n<p><strong>Convalescent plasma therapy</strong> is no longer recommended in the management of COVID patients, as per the revised guidelines.</p>\n<p><strong><span data-preserver-spaces=\"true\">Dexamethasone</span></strong><span data-preserver-spaces=\"true\">&nbsp;is generally given to all patients of moderate and severe COVID-19. Patients with severe COVID-19 can develop a</span><strong><span data-preserver-spaces=\"true\">&nbsp;systemic inflammatory response</span></strong><span data-preserver-spaces=\"true\">&nbsp;that can lead to lung injury and multisystem organ dysfunction. </span></p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8469",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a criterion for discharge in a patient with mild COVID-19 infection?",
      "choices": [
        {
          "id": 1,
          "text": "Discharge after 10 days from testing positive & no fever for 3 days"
        },
        {
          "id": 2,
          "text": "Discharge after 7 days from testing positive & no fever for 3 days"
        },
        {
          "id": 3,
          "text": "Discharge if SpO2>98% on room air for 3 consecutive days"
        },
        {
          "id": 4,
          "text": "Discharge if repeat RT-PCR testing is negative"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>COVID-19 cases that are <strong>mild/very mild/presymptomatic</strong> can be discharged from home isolation after <strong>7</strong><strong>&nbsp;days </strong>of <strong>testing positive</strong><strong>&nbsp;</strong>and<strong> no fever </strong>for<strong> 3 successive days.&nbsp;</strong>There is no need for testing after the end of home isolation.&nbsp;</p>\n<p>Criteria to diagnose asymptomatic COVID-19: Laboratory confirmed case with no symptoms with a saturation of more than 93% in room air.&nbsp;</p>\n<p>Criteria to diagnose mild COVID-19:&nbsp;Laboratory confirmed case with upper respiratory tract symptoms with/without fever, without shortness of breath, and saturation of more than 93% in room air.&nbsp;</p>\n<p>Patients are advised to isolate from other family members and monitor themselves at home, under proper medical guidance.&nbsp;Patients &gt;60 years with co-morbidities, and immunocompromised patients are allowed to isolate only after receiving clearance from the designated medical officer.&nbsp;</p>\n<p>Immediate medical attention is required if the patient experiences the following:&nbsp;</p>\n<ul>\n<li>A 100 &ordm;F fever persists for &gt;3 days and does not resolve on medication.</li>\n<li>Difficulty in breathing&nbsp;</li>\n<li>Oxygen saturation&nbsp;&le;93% (at least 3 readings within 1 hour)</li>\n<li>Respiratory rate&nbsp;&gt;24/min</li>\n<li>Persistent chest pain or pressure</li>\n<li>Mental confusion&nbsp;</li>\n<li>Severe fatigue or myalgia&nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6833",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old male, known case of diabetes mellitus type-2, hypertension, and chronic kidney disease, presents to the ER with complaints of breathing difficulty and fever. On examination, pulse rate is 96 bpm, BP is 118/70 mmHg, the temperature is 100.4 degree F, RR is 15/min and SpO2 is 96%. RT PCR indicates he is COVID positive. Chest CT as shown below demonstrates ground-glass opacities close to the visceral pleural surfaces and visible intralobular lines. Which CO-RADS (COVID-19 Reporting and Data System) category does this patient fall under?",
      "choices": [
        {
          "id": 1,
          "text": "CO-RADS 5"
        },
        {
          "id": 2,
          "text": "CO- RADS 6"
        },
        {
          "id": 3,
          "text": "CO- RADS 4"
        },
        {
          "id": 4,
          "text": "CO - RADS 7"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>As the patient has a positive COVID RT PCR, he would be classified as CORADS 6 - irrespective of his CT appearance.</p>\n<p>&nbsp;</p><p>CO-RADS Categories</p>\n<p><strong>CO-RADS 0 (Not interpretable - Technically insufficient to assign a score)</strong>: Scans are incomplete or of inferior quality.</p>\n<p><strong>CO-RADS 1 (Very low risk - Normal/Non-infectious):</strong> Very low level of suspicion for pulmonary involvement by COVID-19. Mild or severe emphysema, perifissural nodules, lung tumors, or fibrosis.</p>\n<p><strong>CO-RADS 2 (Low - Typical for other infections but not COVID-19):</strong> Low level of suspicion for pulmonary involvement by COVID-19. Includes infectious etiology that is not compatible with COVID-19 such as bronchitis, bronchiolitis, bronchopneumonia, lobar pneumonia, abscess.</p>\n<p><strong>CO-RADS 3 (Equivocal - Features compatible with COVID-19, but also other diseases):</strong> Equivocal findings for pulmonary involvement by COVID-19. Findings overlap with other viral or infectious etiologies. Could include perihilar ground-glass, homogenous extensive ground-glass with or without sparing of secondary pulmonary lobules.</p>\n<p><strong>CO-RADS 4 (High - Suspicious for COVID-19):</strong> High level of suspicion for pulmonary involvement by COVID-19. Findings are similar to CO-RADS 5 but are not present in the typical locations. Findings may also be superimposed on severe pre-existing pulmonary abnormalities.</p>\n<p><strong>CO-RADS 5</strong>&nbsp;(<strong>very high level of suspicion for pulmonary involvement by COVID-19)</strong> based on <strong>typical CT findings</strong>. It requires the presence of <strong>at least one confirmatory pattern -&nbsp;</strong>which includes ground glass regions, crazy paving pattern, and/or organizing pneumonia compatible patterns. Thickened vessels with parenchymal abnormalities is found in all confirmatory patterns</p>\n<p><strong>CO-RADS 6 (Proven):</strong> Proven COVID-19 by positive RT-PCR test.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c13e1315a03d49eba7e0b20b6f0097dc.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8474",
      "difficulty": "medium"
    },
    {
      "text": "The median incubation period of the SARS-COV2 virus is?",
      "choices": [
        {
          "id": 1,
          "text": "10- 14 days"
        },
        {
          "id": 2,
          "text": "12 - 24 days"
        },
        {
          "id": 3,
          "text": "4-6 days"
        },
        {
          "id": 4,
          "text": "1-3 days"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>median incubation period</strong> is <strong>around 4-6 days</strong>. The incubation period of SARS-CoV-2 infection ranges from 2-14 days.</p>\n<p><strong>The incubation period</strong> is the time interval between invasion of the infectious agent and appearance of the first symptom or sign in the body. It is termed as the <strong>latent period</strong> in non-infectious diseases. The incubation period depends upon <strong>generation time of the pathogen, the portal of entry, infective dose, and individual susceptibility.</strong></p>\n<p>The <strong>median incubation </strong>period is the <strong>time required for 50% of the cases to occur </strong>after exposure<strong>. </strong></p>\n<p><strong>Application</strong> of incubation period is for</p>\n<ul>\n<li>Tracing the source of infection and contacts</li>\n<li>Determining the period of surveillance or<strong> quarantine</strong></li>\n<li>For immunization</li>\n<li>Identification of point source or propagated epidemics</li>\n<li>Prognosis</li>\n</ul>\n<p>Quarantine is the <strong>limitation</strong> in freedom of movement of healthy contacts of cases, who have been exposed for a period that lasts as much as the <strong>maximal incubation period of the disease. </strong>It is a primary level of prevention, under specific protection. That is why contacts of COVID 19 patients are quarantined for 14 days. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8472",
      "difficulty": "hard"
    },
    {
      "text": "A thirteen-year-old boy was brought to the OPD with fever and cough. His history is significant for frequent fever and painful swelling of hands after playing football. His mother brings an old sonology report which reveals his spleen to be shrunken. His vitals are within normal limits. You order certain radiological investigations and RT-PCR tests for SARS-COV2 and he is diagnosed with mild to moderate COVID. His vitals are stable and hence you decide to treat him on an outpatient basis. You can use all of the following drugs, as part of a combination, to treat the coronavirus disease in this patient except:",
      "choices": [
        {
          "id": 1,
          "text": "Crizanlizumab"
        },
        {
          "id": 2,
          "text": "Casirivimab"
        },
        {
          "id": 3,
          "text": "Bamlanivimab"
        },
        {
          "id": 4,
          "text": "Imdevimab"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The finding of dactylitis along with the shrunken spleen is suggestive of <strong>sickle cell disease</strong>.</p>\n<p><strong> Crizanlizumab</strong> is a <strong>selectin blocker</strong> indicated to <strong>reduce the frequency of vasoocclusive crises</strong> in adults and pediatric patients aged 16 years and older with sickle cell disease. It is not used to treat COVID.</p>\n<p><span data-preserver-spaces=\"true\">The FDA has given emergency use authorization for the use of the </span><span data-preserver-spaces=\"true\">following combination anti-SARS-CoV-2 monoclonal antibodies to treat outpatients with mild to moderate COVID-19 who are at high risk of clinical progression:<br /></span></p>\n<ul>\n<li><span data-preserver-spaces=\"true\"><strong>Bamlanivimab 700 mg plus etesevimab 1,400 mg</strong> administered together</span></li>\n<li><span data-preserver-spaces=\"true\"><strong>Casirivimab 1,200 mg plus imdevimab 1,200 mg</strong> administered together</span></li>\n</ul>\n<p><span data-preserver-spaces=\"true\"><strong>Bamlanivimab</strong> and <strong>etesevimab</strong> are <strong>neutralizing IgG1 monoclonal antibodies</strong> that <strong>bind to distinct but overlapping epitopes</strong> within the <strong>receptor-binding domain of the spike protein of SARS-CoV2</strong>. </span></p>\n<p><span data-preserver-spaces=\"true\"><strong>Casirivimab</strong> and <strong>imdevimab</strong> are also <strong>IgG1 monoclonal antibodies</strong> that bind to non-overlapping epitopes of the <strong>spike protein receptor-binding domain</strong> (RBD) of SARS-CoV-2 and <strong>block the RBD binding to the human ACE2 receptor. </strong></span><span data-preserver-spaces=\"true\">The FDA has issued an emergency use authorization for using this combination for the treatment of adult and pediatric mild to moderate COVID patients (12 years of age and older weighing at least 40 kilograms) who are at high risk for progressing to severe COVID-19 and/or hospitalization.</span></p>\n<p><strong>Indication:</strong></p>\n<p><strong>High-Risk Criteria for Emergency Use Authorization</strong></p>\n<p>High-risk individuals who at least one of the following criteria:</p>\n<ul>\n<li>BMI ≥35</li>\n<li>Chronic kidney disease</li>\n<li>Diabetes mellitusImmunocompromising condition</li>\n<li>Currently receiving immunosuppressive treatment</li>\n<li>Aged ≥65 years</li>\n<li>Aged ≥55 years and have Cardiovascular disease; or Hypertension; or Chronic obstructive pulmonary disease/other chronic respiratory diseases.</li>\n</ul>\n<p>For those between 12 - 17 years: (either of the following)</p>\n<ul>\n<li>BMI ≥85th percentile for their age and gender-based on the Centers for Disease Control and Prevention growth charts</li>\n<li><strong>Sickle cell disease</strong></li>\n<li>Congenital or acquired heart disease</li>\n<li> Neurodevelopmental disorders, for example, cerebral palsy</li>\n<li>A medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)</li>\n<li>Asthma or a reactive airway or other chronic respiratory diseases that require daily medication <br />for control.</li>\n</ul><p><span data-preserver-spaces=\"true\">The following parameters should raise the suspicion of COVID sepsis in a pediatric population: </span></p>\n<p><span data-preserver-spaces=\"true\">Hypotension ( SBP &lt; 5th centile or &gt; 2SD below normal for age)</span></p>\n<p><span data-preserver-spaces=\"true\">OR</span></p>\n<p><span data-preserver-spaces=\"true\">Presence of any two of the following:</span></p>\n<ol>\n<li><span data-preserver-spaces=\"true\">altered mental state</span></li>\n<li><span data-preserver-spaces=\"true\">Tachycardia / Bradycardia (HR &lt;70 bpm or HR &gt;150 bpm in children) (HR &lt; 90 bpm or HR &gt; 160bpm in infants )</span></li>\n<li><span data-preserver-spaces=\"true\">Prolonged capillary refill time &gt;2sec</span></li>\n<li><span data-preserver-spaces=\"true\">warm vasodilation with bounding pulses</span></li>\n<li><span data-preserver-spaces=\"true\">Skin changes - mottling, petechiae rash, purpura</span></li>\n<li><span data-preserver-spaces=\"true\">increased lactate &gt; 2mmol</span></li>\n<li><span data-preserver-spaces=\"true\">Oliguria</span></li>\n<li><span data-preserver-spaces=\"true\">Temperature changes - Hypo / Hyperthermia. </span></li>\n</ol>\n<p>Management:</p>\n<ul>\n<li>Treat as severe COVID pneumonia</li>\n<li><span data-preserver-spaces=\"true\">early recognition</span></li>\n<li><span data-preserver-spaces=\"true\">vasopressors</span></li>\n<li><span data-preserver-spaces=\"true\">antimicrobials within <strong>1 hour</strong></span></li>\n<li><strong><strong>Avoid hypotonic crystalloids, gelatins for </strong></strong><strong><span data-preserver-spaces=\"true\">resuscitation.</span></strong></li>\n<li><span data-preserver-spaces=\"true\">Signs of poor perfusion / cardiac dysfunction - add inotropes - <strong>Dobutamine</strong></span></li>\n</ul>\n<p><span data-preserver-spaces=\"true\">Target:</span></p>\n<ul>\n<li><strong>Mean Arterial Pressure &gt; 65mm of Hg.</strong></li>\n<li><span data-preserver-spaces=\"true\">urine output (&gt;0.5ml/kg/hr in adults and &gt;1ml/kg/hr in children</span></li>\n<li><span data-preserver-spaces=\"true\">Improve skin mottling</span></li>\n<li><span data-preserver-spaces=\"true\">capillary refill - WNL</span></li>\n<li><span data-preserver-spaces=\"true\">Level of conciousness - normal </span></li>\n<li><span data-preserver-spaces=\"true\">Serum lactate levels - lowered </span></li>\n</ul><p>In sickle cell disease, repeated splenic micro-infarcts cause loss of splenic function and shrinkage. Vaso-occlusion causes hand-foot syndrome with painful infarction of the digits and dactylitis.</p>\n<p>Other manifestations include:</p>\n<ul>\n<li>Acute splenic sequestration due to venous obstruction, necessitating emergency transfusion/splenectomy</li>\n<li>Painful ischemic crises due to vaso-occlusion in connective and musculoskeletal tissue</li>\n<li>Renal papillary necrosis leading to isosthenuria</li>\n<li>Cerebrovascular strokes</li>\n<li>Chronic lower leg ulcers</li>\n<li>Priapism in males</li>\n</ul><p>NOTE:</p>\n<p>FDA has recently expanded the emergency use authorization for the monoclonal antibody combination <strong>Bamlanivimab and Etesevimab.</strong> It can now be used for the treatment of mild to moderate COVID-19 and for post-exposure prophylaxis in all patients, including newborns who are at high risk for progression to severe COVID-19.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8476",
      "difficulty": "hard"
    },
    {
      "text": "A 45-year-old African-American presents to you with puffiness of the face, edema of feet, and oliguria. Past history was significant for COVID 19 disease. He was on home quarantine for 17 days. It has been a week since his quarantine period got over. The histopathological image of a section of his kidney is indicative of collapsing glomerulopathy and appears as shown below. Which of the following genes increases the risk of this disease entity in COVID-19 patients?",
      "choices": [
        {
          "id": 1,
          "text": "NPHS1"
        },
        {
          "id": 2,
          "text": "ACTN4"
        },
        {
          "id": 3,
          "text": "APOL1"
        },
        {
          "id": 4,
          "text": "TRPC6"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Apolipoprotein L1 (<em>APOL1</em>) gene </strong>increases the risk of <strong>collapsing nephropathy</strong> in <strong>patients infected with COVID-19</strong>. The given HP section shows collapsing nephropathy with <strong>microcystic tubular dilatation and tubular injury.</strong></p>\n<p>This type of COVID-19-​associated nephropathy (COVAN) specifically affects individuals of <strong>African ancestry</strong> who are carriers of this gene variant. Histopathology is similar to those seen in other forms of collapsing glomerulopathy. But, <strong>tubulointerstitial lesions</strong> including microcystic tubular dilatation and tubular injury are typically associated with APOL1- related disease. </p>\n<p> </p>\n<p>The proposed pathogenesis of COVAN is as follows:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8eee5f0d7bc4404e92e7c72bf81465d0x685x325.JPEG\" alt=\"Explanation Image\"><p>Pathogenesis involves activation of the interferon-chemokine pathway, which interacts with the APOL1 variant gene leading to tubuloreticular lesions and inclusions described as '<strong>Interferon footprints</strong>'.</p>\n<p>It is interesting to note that collapsing glomerulopathy was first characterized in individuals with HIV infection and became recognized as the classic histomorphological form of HIV-associated nephropathy (HIVAN).</p>\n<p>Other causes of collapsing glomerulopathy:</p>\n<ul>\n<li>HIV</li>\n<li>SLE</li>\n<li>Parvovirus B19</li>\n<li>CMV</li>\n<li>EBV</li>\n<li>Hemophagocytic Lymphohistiocytosis</li>\n<li>PLA-2R associated membranous nephropathy. </li>\n</ul><hr><h3>Related Pearl: Glomerular Pathology in Renal Diseases</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td><strong>Light microscopy</strong></td>\n<td><strong>Fluorescence microscopy</strong></td>\n<td>\n<p><strong>Electron microscopy</strong></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"4\">\n<p>Nephritic syndrome:</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Postinfectious glomerulo-nephritis</p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Diffuse endocapillary proliferation; leukocytic infiltration</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Granular IgG and C3 in glomerular basement membrane and mesangium,&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Granular IgA in some cases</p>\n</div>\n</div>\n</div>\n</div>\n&nbsp;</td>\n<td>\n<p><strong>Subepithelial humps </strong>Subendothelial deposits in early disease stages</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Goodpasture syndrome</p>\n</td>\n<td>Extracapillary proliferation with <strong>crescents</strong>; necrosis</td>\n<td>&nbsp;<strong>Linear </strong>IgG and C3; fibrin in crescents</td>\n<td>\n<p><strong>Linear deposits</strong><strong><strong>&nbsp;</strong></strong>along the basement membrane.&nbsp;</p>\n<p><strong>Disruptions in GBM</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>IgA nephropathy (Berger disease)</p>\n</td>\n<td>Focal mesangial proliferative glomerulo-nephritis; mesangial widening</td>\n<td>&nbsp;<strong>IgA</strong> &plusmn; IgG, IgM, and C3 in mesangium</td>\n<td><strong>Mesangial </strong>and paramesangial dense deposits&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Alport syndrome</p>\n</td>\n<td>Normal</td>\n<td>Negative</td>\n<td><strong>Basket-weave appearance </strong>of GBM</td>\n</tr>\n<tr>\n<td colspan=\"4\">\n<p>Nephrotic syndrome:</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Membranous&nbsp; nephropathy</p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Diffuse capillary wall thickening</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Granular IgG and C3; diffuse</p>\n</div>\n</div>\n</div>\n</div>\n&nbsp;</td>\n<td>\n<p><strong>Subepithelial deposits </strong>(epimembranous spikes),&nbsp;effacement of podocyte&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Minimal change disease</p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Normal; lipid in tubules</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>Negative&nbsp;</td>\n<td>\n<p>No deposits.</p>\n<p>Effacement of podocyte&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Focal segmental glomerulo-sclerosis&nbsp; (FSGS)</p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Glomerular hyalinosis and sclerosis</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>Occasional C3 and IgM deposits in the sclerotic areas and the mesangium.</td>\n<td>\n<p>No deposits.</p>\n<p>Effacement of podocyte&nbsp;</p>\n<p>Epithelial denudation.</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"4\">\n<p>Nephrito-nephrotic syndrome:&nbsp;&nbsp;&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Membrano-proliferative glomerulo-nephritis</p>\n<p>(MPGN) type I</p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Mesangial proliferative pattern of proliferation; GBM thickening; splitting</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C3, C1q, C4 deposits&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\nIgG deposits</td>\n<td>\n<p><strong>Subendothelial deposits</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Dense-deposit disease (MPGN type II)</p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Mesangial proliferative&nbsp; pattern of proliferation; GBM thickening; splitting</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>\n<div class=\"page\" title=\"Page 915\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>C3 deposits;</p>\n<p>No C1q and C4 deposits</p>\n<p>No IgG deposits</p>\n</div>\n</div>\n</div>\n</div>\n&nbsp;</td>\n<td>\n<p><strong>Intramembranous </strong>Dense deposits</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Fibrillary glomerulo-nephritis</p>\n</td>\n<td>&nbsp;\n<div class=\"page\" title=\"Page 931\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Membrano-proliferative or mesangio-proliferative patterns</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>IgG4 and C3&nbsp;</td>\n<td>Fibrillar deposits in the mesangium and capillary walls</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>Note:</p>\n<ul>\n<li>Anionic antigens form subendothelial deposits.</li>\n<li>Cationic antigens form subepithelial deposits.</li>\n<li>Neutral antigens form mesangial deposits.</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/5de2d26fc1cb40eb870ceb8da01b4139.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8480",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is least likely to be useful in a patient with severe COVID-19?",
      "choices": [
        {
          "id": 1,
          "text": "Low molecular weight heparin"
        },
        {
          "id": 2,
          "text": "Oxygen"
        },
        {
          "id": 3,
          "text": "Favipiravir"
        },
        {
          "id": 4,
          "text": "Steroids"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Favipiravir(inhibits viral RNA polymerase) is the first oral drug approved in India for restricted emergency use for the treatment of mild to moderate COVID-19 patients. Studies show that the drug offers a rapid reduction in viral load and also provides a faster symptomatic and radiological improvement.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:895,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16777215},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">Favipiravir (inhibits viral RNA polymerase) was the first oral drug approved in India for restricted emergency use for the treatment of <strong>mild to moderate COVID-19</strong> patients. It was <strong>not approved</strong> for <strong>severe COVID-19</strong>.&nbsp;</span></p>\n<p>&nbsp;</p>\n<p>Note: This is a question from INICET 2020, during which time&nbsp;<span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Favipiravir(inhibits viral RNA polymerase) is the first oral drug approved in India for restricted emergency use for the treatment of mild to moderate COVID-19 patients. Studies show that the drug offers a rapid reduction in viral load and also provides a faster symptomatic and radiological improvement.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:895,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:16777215},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:1,&quot;11&quot;:4,&quot;12&quot;:0}\">Favipiravir</span> had gained approval from DCGI for mild to moderate COVID. The current clinical management protocol for COVID-19 does not recommend Favipiravir.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6618",
      "difficulty": "easy"
    },
    {
      "text": "The specimens collected for COVID-19 testing should be transported to the lab at what temperatures?",
      "choices": [
        {
          "id": 1,
          "text": "-30 degree C"
        },
        {
          "id": 2,
          "text": "-4 to -8 degree C"
        },
        {
          "id": 3,
          "text": "2 to 8 degree C"
        },
        {
          "id": 4,
          "text": "12 to 16 degree C"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Specimens collected for COVID-19 testing should be transported to the lab at a temperature of <strong>2 to 8 degrees C</strong> as per the <strong>WHO</strong> guidelines. The <strong>ICMR/NIV</strong> guidelines recommend <strong>4 degrees C</strong> for transport to the laboratory.&nbsp;</p>\n<p>Both guidelines recommend storing specimens at <strong>-70&deg;C or below</strong> if a <strong>delay</strong> in testing or shipping is expected.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Specimen</strong></td>\n<td><strong>Sensitivity</strong></td>\n</tr>\n<tr>\n<td>Bronchoalveolar lavage fluid</td>\n<td>93%</td>\n</tr>\n<tr>\n<td>Sputum</td>\n<td>72%</td>\n</tr>\n<tr>\n<td>Nasopharyngeal swab</td>\n<td>63%</td>\n</tr>\n<tr>\n<td>Oropharyngeal swab</td>\n<td>32%</td>\n</tr>\n<tr>\n<td>Faeces</td>\n<td>29%</td>\n</tr>\n<tr>\n<td>Blood</td>\n<td>1%</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6839",
      "difficulty": "easy"
    }
  ]
}